Clinical correlations are emerging; Microfibril-Associated Glycoprotein 2 (MFAP2) plus CAFs in GC have been shown to impair responses to both chemotherapy and immunotherapy through macrophage migration inhibitory factor (MIF)-mediated immune modulation [148]. This evidence concerns the gene MIF and gastric cancer.